define(['dart_sdk', 'packages/flutter/src/painting/image_resolution.dart', 'packages/flutter/src/foundation/change_notifier.dart'], (function load__packages__pediatric_dosage__providers__dosage_provider_dart(dart_sdk, packages__flutter__src__painting__image_resolution$46dart, packages__flutter__src__foundation__change_notifier$46dart) {
  'use strict';
  const core = dart_sdk.core;
  const _interceptors = dart_sdk._interceptors;
  const dart = dart_sdk.dart;
  const dartx = dart_sdk.dartx;
  const image_resolution = packages__flutter__src__painting__image_resolution$46dart.src__painting__image_resolution;
  const change_notifier = packages__flutter__src__foundation__change_notifier$46dart.src__foundation__change_notifier;
  var dosage_provider = Object.create(dart.library);
  var $where = dartx.where;
  var $toList = dartx.toList;
  dart._checkModuleNullSafetyMode(false);
  var T = {
    CategoryL: () => (T.CategoryL = dart.constFn(dart.legacy(dosage_provider.Category)))(),
    JSArrayOfCategoryL: () => (T.JSArrayOfCategoryL = dart.constFn(_interceptors.JSArray$(T.CategoryL())))(),
    ListOfCategoryL: () => (T.ListOfCategoryL = dart.constFn(core.List$(T.CategoryL())))(),
    StringL: () => (T.StringL = dart.constFn(dart.legacy(core.String)))(),
    JSArrayOfStringL: () => (T.JSArrayOfStringL = dart.constFn(_interceptors.JSArray$(T.StringL())))(),
    DrugL: () => (T.DrugL = dart.constFn(dart.legacy(dosage_provider.Drug)))(),
    JSArrayOfDrugL: () => (T.JSArrayOfDrugL = dart.constFn(_interceptors.JSArray$(T.DrugL())))(),
    ListOfDrugL: () => (T.ListOfDrugL = dart.constFn(core.List$(T.DrugL())))(),
    boolL: () => (T.boolL = dart.constFn(dart.legacy(core.bool)))(),
    DrugLToboolL: () => (T.DrugLToboolL = dart.constFn(dart.fnType(T.boolL(), [T.DrugL()])))()
  };
  var T$Eval = Object.assign({
    _: () => T$Eval
  }, T);
  var S = {
    _: () => S
  };
  var S$Eval = Object.assign({
    _: () => S$Eval
  }, S);
  const CT = Object.create({
    _: () => (C, CT)
  });
  var C = [];
  var I = ["package:pediatric_dosage/providers/dosage_provider.dart"];
  var id$ = dart.privateName(dosage_provider, "Category.id");
  var name$ = dart.privateName(dosage_provider, "Category.name");
  var image$ = dart.privateName(dosage_provider, "Category.image");
  dosage_provider.Category = class Category extends core.Object {
    get id() {
      return this[id$];
    }
    set id(value) {
      super.id = value;
    }
    get name() {
      return this[name$];
    }
    set name(value) {
      super.name = value;
    }
    get image() {
      return this[image$];
    }
    set image(value) {
      super.image = value;
    }
  };
  (dosage_provider.Category.new = function(id, name, image) {
    this[id$] = id;
    this[name$] = name;
    this[image$] = image;
    ;
  }).prototype = dosage_provider.Category.prototype;
  dart.addTypeTests(dosage_provider.Category);
  dart.addTypeCaches(dosage_provider.Category);
  dart.setLibraryUri(dosage_provider.Category, I[0]);
  dart.setFieldSignature(dosage_provider.Category, () => ({
    __proto__: dart.getFields(dosage_provider.Category.__proto__),
    id: dart.finalFieldType(dart.legacy(core.String)),
    name: dart.finalFieldType(dart.legacy(core.String)),
    image: dart.finalFieldType(dart.legacy(image_resolution.AssetImage))
  }));
  var _categories = dart.privateName(dosage_provider, "_categories");
  const Object_ChangeNotifier$36 = class Object_ChangeNotifier extends core.Object {};
  (Object_ChangeNotifier$36.new = function() {
    change_notifier.ChangeNotifier.new.call(this);
  }).prototype = Object_ChangeNotifier$36.prototype;
  dart.applyMixin(Object_ChangeNotifier$36, change_notifier.ChangeNotifier);
  dosage_provider.CategoryProvider = class CategoryProvider extends Object_ChangeNotifier$36 {
    get categories() {
      return (() => {
        let t0 = T.ListOfCategoryL().of(this[_categories]);
        return t0;
      })();
    }
  };
  (dosage_provider.CategoryProvider.new = function() {
    this[_categories] = T.JSArrayOfCategoryL().of([new dosage_provider.Category.new("a", "Antipyretic", new image_resolution.AssetImage.new("assets/images/fever.png")), new dosage_provider.Category.new("b", "Common Cold", new image_resolution.AssetImage.new("assets/images/commoncold.png")), new dosage_provider.Category.new("c", "Antibiotics", new image_resolution.AssetImage.new("assets/images/antibiotics.png")), new dosage_provider.Category.new("d", "GIT", new image_resolution.AssetImage.new("assets/images/git.png")), new dosage_provider.Category.new("e", "Respiratory", new image_resolution.AssetImage.new("assets/images/respiratory.png"))]);
    dosage_provider.CategoryProvider.__proto__.new.call(this);
    ;
  }).prototype = dosage_provider.CategoryProvider.prototype;
  dart.addTypeTests(dosage_provider.CategoryProvider);
  dart.addTypeCaches(dosage_provider.CategoryProvider);
  dart.setGetterSignature(dosage_provider.CategoryProvider, () => ({
    __proto__: dart.getGetters(dosage_provider.CategoryProvider.__proto__),
    categories: dart.legacy(core.List$(dart.legacy(dosage_provider.Category)))
  }));
  dart.setLibraryUri(dosage_provider.CategoryProvider, I[0]);
  dart.setFieldSignature(dosage_provider.CategoryProvider, () => ({
    __proto__: dart.getFields(dosage_provider.CategoryProvider.__proto__),
    [_categories]: dart.fieldType(dart.legacy(core.List$(dart.legacy(dosage_provider.Category))))
  }));
  var id$0 = dart.privateName(dosage_provider, "Drug.id");
  var cat$ = dart.privateName(dosage_provider, "Drug.cat");
  var genericName$ = dart.privateName(dosage_provider, "Drug.genericName");
  var tradeName$ = dart.privateName(dosage_provider, "Drug.tradeName");
  var conc$ = dart.privateName(dosage_provider, "Drug.conc");
  var contra$ = dart.privateName(dosage_provider, "Drug.contra");
  var prec$ = dart.privateName(dosage_provider, "Drug.prec");
  var minD$ = dart.privateName(dosage_provider, "Drug.minD");
  var maxD$ = dart.privateName(dosage_provider, "Drug.maxD");
  var freq$ = dart.privateName(dosage_provider, "Drug.freq");
  var doseNote$ = dart.privateName(dosage_provider, "Drug.doseNote");
  dosage_provider.Drug = class Drug extends core.Object {
    get id() {
      return this[id$0];
    }
    set id(value) {
      super.id = value;
    }
    get cat() {
      return this[cat$];
    }
    set cat(value) {
      super.cat = value;
    }
    get genericName() {
      return this[genericName$];
    }
    set genericName(value) {
      super.genericName = value;
    }
    get tradeName() {
      return this[tradeName$];
    }
    set tradeName(value) {
      super.tradeName = value;
    }
    get conc() {
      return this[conc$];
    }
    set conc(value) {
      super.conc = value;
    }
    get contra() {
      return this[contra$];
    }
    set contra(value) {
      super.contra = value;
    }
    get prec() {
      return this[prec$];
    }
    set prec(value) {
      super.prec = value;
    }
    get minD() {
      return this[minD$];
    }
    set minD(value) {
      super.minD = value;
    }
    get maxD() {
      return this[maxD$];
    }
    set maxD(value) {
      super.maxD = value;
    }
    get freq() {
      return this[freq$];
    }
    set freq(value) {
      super.freq = value;
    }
    get doseNote() {
      return this[doseNote$];
    }
    set doseNote(value) {
      super.doseNote = value;
    }
  };
  (dosage_provider.Drug.new = function(opts) {
    let id = opts && 'id' in opts ? opts.id : null;
    let genericName = opts && 'genericName' in opts ? opts.genericName : null;
    let tradeName = opts && 'tradeName' in opts ? opts.tradeName : null;
    let conc = opts && 'conc' in opts ? opts.conc : null;
    let cat = opts && 'cat' in opts ? opts.cat : null;
    let contra = opts && 'contra' in opts ? opts.contra : null;
    let maxD = opts && 'maxD' in opts ? opts.maxD : null;
    let minD = opts && 'minD' in opts ? opts.minD : null;
    let freq = opts && 'freq' in opts ? opts.freq : null;
    let doseNote = opts && 'doseNote' in opts ? opts.doseNote : null;
    let prec = opts && 'prec' in opts ? opts.prec : null;
    this[id$0] = id;
    this[genericName$] = genericName;
    this[tradeName$] = tradeName;
    this[conc$] = conc;
    this[cat$] = cat;
    this[contra$] = contra;
    this[maxD$] = maxD;
    this[minD$] = minD;
    this[freq$] = freq;
    this[doseNote$] = doseNote;
    this[prec$] = prec;
    ;
  }).prototype = dosage_provider.Drug.prototype;
  dart.addTypeTests(dosage_provider.Drug);
  dart.addTypeCaches(dosage_provider.Drug);
  dart.setLibraryUri(dosage_provider.Drug, I[0]);
  dart.setFieldSignature(dosage_provider.Drug, () => ({
    __proto__: dart.getFields(dosage_provider.Drug.__proto__),
    id: dart.finalFieldType(dart.legacy(core.String)),
    cat: dart.finalFieldType(dart.legacy(core.String)),
    genericName: dart.finalFieldType(dart.legacy(core.String)),
    tradeName: dart.finalFieldType(dart.legacy(core.String)),
    conc: dart.finalFieldType(dart.legacy(core.double)),
    contra: dart.finalFieldType(dart.legacy(core.List$(dart.legacy(core.String)))),
    prec: dart.finalFieldType(dart.legacy(core.List$(dart.legacy(core.String)))),
    minD: dart.finalFieldType(dart.legacy(core.double)),
    maxD: dart.finalFieldType(dart.legacy(core.double)),
    freq: dart.finalFieldType(dart.legacy(core.String)),
    doseNote: dart.finalFieldType(dart.legacy(core.String))
  }));
  var _drugs = dart.privateName(dosage_provider, "_drugs");
  const Object_ChangeNotifier$36$ = class Object_ChangeNotifier extends core.Object {};
  (Object_ChangeNotifier$36$.new = function() {
    change_notifier.ChangeNotifier.new.call(this);
  }).prototype = Object_ChangeNotifier$36$.prototype;
  dart.applyMixin(Object_ChangeNotifier$36$, change_notifier.ChangeNotifier);
  dosage_provider.AntipyreticProvider = class AntipyreticProvider extends Object_ChangeNotifier$36$ {
    get drugs() {
      return (() => {
        let t1 = T.ListOfDrugL().of(this[_drugs]);
        return t1;
      })();
    }
    get antipyretics() {
      return this[_drugs][$where](dart.fn(element => element.cat === "Antipyretic", T.DrugLToboolL()))[$toList]();
    }
    get antibiotics() {
      return this[_drugs][$where](dart.fn(element => element.cat === "Antibiotics", T.DrugLToboolL()))[$toList]();
    }
    get commomCold() {
      return this[_drugs][$where](dart.fn(element => element.cat === "Common Cold", T.DrugLToboolL()))[$toList]();
    }
    get git() {
      return this[_drugs][$where](dart.fn(element => element.cat === "GIT", T.DrugLToboolL()))[$toList]();
    }
    get respiratory() {
      return this[_drugs][$where](dart.fn(element => element.cat === "Respiratory", T.DrugLToboolL()))[$toList]();
    }
  };
  (dosage_provider.AntipyreticProvider.new = function() {
    this[_drugs] = T.JSArrayOfDrugL().of([new dosage_provider.Drug.new({id: "a", tradeName: "Cetal 250mg/5ml 60ml susp", genericName: "Paracetamol", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 250, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "b", tradeName: "BRUFEN 100MG/5ML SUSP. 150ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "c", tradeName: "ALPHAFEN 100MG/5ML SUSP. 120 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "d", tradeName: "ALPHAFEN 100MG/5ML SUSP. 60 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "e", tradeName: "CETAFEN-N 120ML SUSP.", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "f", tradeName: "CONTAFEVER N 200MG/5ML SUSP. 120ML", cat: "Antipyretic", genericName: "Ibuprofen 200MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 200, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "g", tradeName: "IBUCALMIN 100MG/5ML SYRUP 120 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "h", tradeName: "IBUFEN 2% SUSP. 120ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "i", tradeName: "IBUFEN 2% SUSP. 60ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "j", tradeName: "IBUFLAM N 120ML SUSP.", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "k", tradeName: "IBUPROFEN 100MG/5ML SUSP. 120 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "l", tradeName: "JUSPOLED 100MG/5ML SUSP. 120 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "m", tradeName: "MARCOFEN 100MG/5ML SUSP. 120ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "n", tradeName: "MEGAFEN-N 100MG/5ML SUSP. 120 ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "o", tradeName: "NOVA-PROFEN  100MG/5ML ORAL SUSP. 100ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "p", tradeName: "PROFINAL PAEDIATRIC 20MG/ML SUSP. 110ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "q", tradeName: "PROFINAL PAEDIATRIC 20MG/ML SUSP. 60ML", cat: "Antipyretic", genericName: "Ibuprofen 100MG/5ML SUSP", prec: T.JSArrayOfStringL().of(["Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "Heart Failure (HF) risk", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"]), minD: 5.0, maxD: 10.0, conc: 5 / 100, freq: "PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day", doseNote: "<6 monthsSafety and efficacy not established", contra: T.JSArrayOfStringL().of(["Hypersensitivity to drug, other NSAIDs, aspirin, or excipients", "Perioperative pain in setting of coronary artery bypass graft (CABG) surgery"])}), new dosage_provider.Drug.new({id: "r", tradeName: "ABIMOL 150MG/5ML 125ML SYRUP", genericName: "Paracetamol 150MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 150, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "s", tradeName: "CETAMOL 120MG/5ML PEDIATRIC SYRUP 120 ML", genericName: "Paracetamol 120MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 120, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "t", tradeName: "FEVANO 200MG/5ML SYRUP 125ML", genericName: "Paracetamol 200MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 200, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "u", tradeName: "PARACETAMOL-AMRIYA 120MG/5ML 120ML SUSP.", genericName: "Paracetamol 120MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 120, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "v", tradeName: "PARAMOL 120MG/5ML SYRUP 125ML", genericName: "Paracetamol 120MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 120, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "x", tradeName: "TEMPORAL 250MG/5ML SUSP. 60 ML", genericName: "Paracetamol 250MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 250, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "y", tradeName: "TEMPRA 160 MG/5ML SYP. 90 ML", genericName: "Paracetamol 160MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 160, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "z", tradeName: "THERA-LO 3.2G/100ML ORAL SUSP. 100 ML", genericName: "Paracetamol 160MG/5ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe active liver disease"]), conc: 5 / 160, minD: 10.0, maxD: 15.0, freq: "PO q6-8hr prn", doseNote: "", prec: T.JSArrayOfStringL().of(["Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur", " Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose", " Use caution in patients with hepatic impairment or active liver disease", " Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product", " Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage", " Use with caution in patients with G6PD deficiency", " Use caution in patients with chronic malnutrition", " Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash", " Limit acetaminophen dose from all sources and routes to <4 g/day in adults"])}), new dosage_provider.Drug.new({id: "aa", tradeName: "CATAFLY 2MG/ML SUSP. 140ML", genericName: "Diclofenac potassium 2MG/ML", cat: "Antipyretic", contra: T.JSArrayOfStringL().of(["Absolute: Hypersensitivity to diclofenac, history of aspirin triad, treatment of perioperative pain associated with CABG; active gastrointestinal bleeding", "IV: Moderate-to severe renal insufficiency in the perioperative period and patients who are at risk for volume depletion"]), conc: 1 / 2, minD: 2.0, maxD: 3.0, freq: "PO /day for up to 4 weeks", doseNote: "<3 years: Safety and efficacy not established", prec: T.JSArrayOfStringL().of(["Use caution in patients with bronchospasm, cardiac disease, CHF, hepatic porphyria, hypertension, fluid retention, severe renal impairment, smoking, systemic lupus erythematosus", "Platelet aggregation and adhesion may be decreased; may prolong bleeding time", "Use caution in blood dyscrasias or bone marrow depression; also with thrombocytopenia, agranulocytosis, and aplastic anemia", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals, those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers", "Therapy may increase risk of hyperkalemia, especially in renal disease, diabetics, the elderly, and concomitant use of agents that may induce hyperkalemia; monitor potassium closely", "May cause dizziness blurred vision and neurologic effects that may impair physical and mental abilities", "Risk of serious skin reactions, including Stevens Johnson syndrome and necrotizing enterocolitis", "Persistent urinary symptoms, including bladder pain and dysuria, hematuria or cystitis may occur after initiating therapy; discontinue therapy with symptom onset and evaluate cause", "Increase in transaminase levels reported within 2 months of therapy; may occur at any time; monitor transaminase levels periodically beginning 4-8 weeks after initiation of therapy", "May increase risk of aseptic meningitis (rare), especially in patients with systemic lupus erythrmatosus, and mixed connective tissue disorders", "Use caution if patient dehydrated before initiating therapy; rehydrate patient before initiating therapy and monitor renal function closely", "Injectable dosage form not recommended for long-term use", "Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache); may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks; detoxification of patients, including withdrawal of overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary", "Different formulations not bioequivalent even if milligram strength the same; do not interchange products", "Withhold for at least 4-6 half-lives prior to surgical or dental procedures", "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics", "NSAIDS should be avoided or withdrawn whenever possible"])}), new dosage_provider.Drug.new({id: "ab", tradeName: "1  2  3 (ONE TWO THREE) SYRUP 120 ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "ac", tradeName: "ACTIFED SYRUP 120ML", genericName: "PSEUDOEPHEDRINE+TRIPROLIDINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose"])}), new dosage_provider.Drug.new({id: "ad", tradeName: "ADVIPRO COUGH & COLD SYRUP 120ML", genericName: "CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "ae", tradeName: "ADVIPRO COUGH & COLD SYRUP 120ML", genericName: "CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "af", tradeName: "COLD STOP SYRUP 120 ML", genericName: "CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "ag", tradeName: "CONGESTAL SYRUP 120ML", genericName: "CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "ah", tradeName: "BABYRHINO SYRUP 100ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "ai", tradeName: "FEVER N FLU 120ML SYRUP", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "aj", tradeName: "FLUMOL SYRUP 120ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "ak", tradeName: "NOFLU SYRUP 100ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "al", tradeName: "NEO-MICHAELON SUSP. 120ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "am", tradeName: "RHINOCALM SYRUP 120ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "an", tradeName: "RHINOMOL-S SYRUP 120ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "ao", tradeName: "VEGASKINE SYRUP 120ML", genericName: "CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)"])}), new dosage_provider.Drug.new({id: "ap", tradeName: "CEVANDRA SYRUP 120 ML", genericName: "DEXTROMETHORPHAN+DOXYLAMINE SUCCINATE+PARACETAMOL(ACETAMINOPHEN)", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Not to exceed 2 weeks of use", "Caution in hepatic failure", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "aq", tradeName: "PENTAFLU SYRUP 100 ML", genericName: "DEXTROMETHORPHAN+DOXYLAMINE SUCCINATE+PARACETAMOL(ACETAMINOPHEN)", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Within 14 days of MAO inhibitor therapy", "Acute asthma, sleep apnea"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Not to exceed 2 weeks of use", "Caution in hepatic failure", "Dextromethorphan:Phenylketonuria: Contains aspartame", "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur", "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton"])}), new dosage_provider.Drug.new({id: "ar", tradeName: "DOLO-D ORAL SUSP. 115 ML", genericName: "IBUPROFEN+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)", "Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery"])}), new dosage_provider.Drug.new({id: "ar", tradeName: "DOLO-D PLUS ORAL SUSP. 115 ML", genericName: "CHLORPHENIRAMINE+IBUPROFEN+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)", "Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose"])}), new dosage_provider.Drug.new({id: "as", tradeName: "DOLO-D PLUS ORAL SUSP. 115 ML", genericName: "CHLORPHENIRAMINE+IBUPROFEN+PSEUDOEPHEDRINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs", prec: T.JSArrayOfStringL().of(["Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation", "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever", "Some products may contain sodium", "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates", "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)", "Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)", "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers", "Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding", "May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported", "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat", "Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE", "Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur", "Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy", "Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely", "May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving", "NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed", "Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke", "Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling", "Not for use right before or after heart surgery", "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose"])}), new dosage_provider.Drug.new({id: "at", tradeName: "HISTARHINE SYRUP 100ML", genericName: "PSEUDOEPHEDRINE+TRIPROLIDINE", cat: "Common Cold", contra: T.JSArrayOfStringL().of(["Hypersensitivity", "Severe hypertension, severe CAD", "Within 14 days of MAO inhibitor therapy"]), conc: 0.0, minD: 0.0, maxD: 0.0, freq: "PO /day for up to 4 weeks", doseNote: "<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs", prec: T.JSArrayOfStringL().of(["May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)", "Antihistamines may cause excitation in young children", "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever", "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur", "Do not exceed recommended dose"])}), new dosage_provider.Drug.new({id: "au", tradeName: "AMOXICID 125MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "av", tradeName: "BIOMOX 125MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aw", tradeName: "E-MOX 125MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "ax", tradeName: "E-MOX 125MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "ay", tradeName: "HICONCIL 125MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "az", tradeName: "HICONCIL 125MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 15.0, maxD: 20.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdz", tradeName: "MOXIPEN 125MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 125MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdsdz", tradeName: "AMOXICID 250MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdvdsdz", tradeName: "AMOXIL FORT 250MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdasdvdsdz", tradeName: "AMOXIL FORT 250MG/5ML SUSP. 100ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdassdfdvdsdz", tradeName: "AMOXYCILLIN 250 MG/5 ML SUSP. 100 ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aas2dassdfdvdsdz", tradeName: "AMOXYCILLIN 250 MG/5 ML SUSP. 80 ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdassdfsdsdfdvdsdz", tradeName: "BIOMOX 250MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdassdfsd4sdfdvdsdz", tradeName: "E-MOX 250MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdassdfsd4sdfd3vdsdz", tradeName: "E-MOX 250MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdassdfsd4sdfdw3vdsdz", tradeName: "HICONCIL 250MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdfsd4sdfdw3vdsdz", tradeName: "HICONCIL 250MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sd4sdfdw3vdsdz", tradeName: "MOXIPEN 250MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 250MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sd4ssdfdw3vdsdz", tradeName: "IBIAMOX 200MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 200MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sd4ssdfdw3vds4dz", tradeName: "DELPEDOX 400MG/5ML PD. FOR ORAL SUSP. 100ML", genericName: "AMOXICILLIN 400MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 400, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdh4ssdfdw3vds4dz", tradeName: "IBIAMOX 400MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN 400MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 400, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdhb4ssdfdw3vds4dz", tradeName: "ORGANOMOX 400MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN 400MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity to penicillins, cephalosporins, imipenem"]), conc: 5 / 400, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins", "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation", "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash", "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria", "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment", "Chewable tablets contain aspartame, which contains phenylalanine", "Use caution in patients with allergy to cephalosporins, carbapenems", "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines", "High doses may cause false urine glucose test by some methods"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdh1b4ssdfdw3vds4dz", tradeName: "AUGMENTIN 156 MG/5 ML SUSP. 80 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q8h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf43sdh1b4ssdfdw3vds4dz", tradeName: "AUGMENTIN 312 MG/5 ML SUSP. 80 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q8h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf43sdh1b4ssdfdw3vds4dz", tradeName: "AUGMENTIN 228 MG/5 ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf43sdh1b4ssdfdw3vds4dz", tradeName: "AUGMENTIN 457 MG/5 ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf43sdh1b4ssdfdwd3vds4dz", tradeName: "AMOCLAWIN 228.5MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddf43sdh1b4ssdfdwd3vds4dz", tradeName: "AMOXILANIC 228.5MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1fdfsdf43sdh1b4ssdfdwd3vds4dz", tradeName: "AMOCLAWIN 457MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddf43sdh1b4sssssdfdwd3vds4dz", tradeName: "AMOXILANIC 457MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457G/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddf43sdh1b4ssdfdwdada3vds4dz", tradeName: "AUGMACILLIN 228.5 MG/5ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1fdfsdf43sdh1b4ssdfdwd3vsdds4dz", tradeName: "AUGMACILLIN 457MG/5ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddddf43sdh1b4ssdfdwdada3vds4dz", tradeName: "AUGRAM 228.5 MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1fdfsdf43sdhsdf1b4ssdfdwd3vsdds4dz", tradeName: "AUGRAM 457 MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddddf43ssssfdh1b4ssdfdwdada3vds4dz", tradeName: "CLAVIMOX 228.5MG/5ML PD. FOR ORAL SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1fsfsddfsdf43sdhsdf1b4ssdfdwd3vsdds4dz", tradeName: "CLAVIMOX 457MG/5ML PD. FOR ORAL 75 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdcvncvh1b4ssdfdw3vds4dz", tradeName: "CLAVIMOX 312.5MG/5ML PD. FOR ORAL 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3saadsdcvncvh1b4ssdfdw3vds4dz", tradeName: "CLAVOSIGMA 250MG/62.5MG SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sw3vdhs4dz", tradeName: "CLAVUCIN 156 MG/5 ML 60ML SUSP. (N/A)", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdddfdfas1sw3vds4dz", tradeName: "CURAM 156.25/5ML PD. FOR ORAL SUSP. 75ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdddfsdfdfas1sw3vds4dz", tradeName: "CURAM 312.5 MG/5ML PD. FOR ORAL SUSP. 75ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdddfsvcnvdfdfas1sw3vds4dz", tradeName: "CURAM 228.5MG/5ML PD. FOR ORAL SUSP. 75ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddcxvdfsdfddgddfas1sw3vds4dz", tradeName: "CURAM 457MG/5ML PD. FOR ORAL SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdddfsvcnvdsdfsfdfas1sw3vds4dz", tradeName: "DELTACLAV 228.5MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddcxvdfsdfsdfsddgdadsdfas1sw3vds4dz", tradeName: "DELTACLAV 457MG/5ML PD. FOR ORAL 80ML SUSP.", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdddfsvcZzcnvdsdfsfdfas1sw3vds4dz", tradeName: "DEXICLAVE 312.5MG/5ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddcxvdfsdfsdsxcvxcdfsdfsddgdadsdfas1sw3vds4dz", tradeName: "DEXICLAVE 457MG/5ML SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdh1sdsb4ssdfdw3vds4dz", tradeName: "E-MOXCLAV 156MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf43sdh1bxcv4ssdfdw3vds4dz", tradeName: "E-MOXCLAV 312 MG/5ML DRY MIX FOR ORAL SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1ssdfdf43sdh1b4ssdfdws3vds4dz", tradeName: "E-MOXCLAV 228.5MG DRY SUSP. 75 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasfs1sdf43sdh1b4ssdfdw3vds4dz", tradeName: "E-MOXCLAV 457MG SUSP. 70 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf3sdhfgh1sdsb4ssdfdw3vds4dz", tradeName: "GARDINOVA 156MG/5ML 70ML SUSP.", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdf4sdf3sdh1bxcv4ssdfdw3vds4dz", tradeName: "GARDINOVA 312MG/5ML 70ML SUSP.", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasfs1sdfsdf43sdh1b4ssdfdw3vds4dz", tradeName: "GARDINOVA 457MG/5ML 70ML SUSP.", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdw3vds4dz", tradeName: "HIBIOTIC 312MG/5 ML 60ML SUSP.", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdas1sdfxvx4sdf3sdh1bxcv4ssdfdw3vds4dz", tradeName: "HIBIOTIC N 228MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasfs1sdfsdf43sdhsfs1b4ssdfdw3vds4dz", tradeName: "HIBIOTIC N 457MG/5ML SUSP. 60ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddz", tradeName: "KLAVOX 228MG/5ML SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasfs1sdfsdf43sdhsfs1b4ssdfsdfdw3vds4dz", tradeName: "KLAVOX 457MG/5ML SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasfs1sdfsdf43sdhsfs", tradeName: "LARYNCLAVE 400/57 PD. FOR ORAL SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdvnvbw3vds4dz", tradeName: "LARYNCLAVE 125/31 PD. FOR ORAL SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdxcvdfgfdxcw3vds4dz", tradeName: "LARYNCLAVE 250/62 PD. FOR ORAL SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdvnvbwghjgh3vds4dz", tradeName: "MAGNABIOTIC 156.25MG/5ML SUSP. 80 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdxcvdfsdfsgfdxcw3vds4dz", tradeName: "MAGNABIOTIC 312.5MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 312MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 312, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdfdvnvbwsdfsghjgh3vds4dz", tradeName: "MEGACLAVOX 156MG/5ML PD. FOR SUSP. 60 ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 156MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 156, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasddsdfsdz", tradeName: "MEGAMOX 228MG SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 228MG/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 228, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdassdfsdfdw3vds4dz", tradeName: "MEGAMOX 457MG/5ML SUSP. 70ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasdfsssdfsdfdw3vds4dz", tradeName: "NEW-CLAV 457MG/5ML SUSP. 80ML", genericName: "AMOXICILLIN/CLAVULANIC ACID 457/5ML", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Allergy to penicillins", "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate", "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"]), conc: 5 / 457, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Allergy to cephalosporins, carbapenems", "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different", "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)", "Incidence of diarrhea is higher than with amoxicillin alone", "Unknown safety and efficacy of extended-release tablets in patients <16 years old", "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment", "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy", "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients", "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy"])}), new dosage_provider.Drug.new({id: "aasdasxfbdfsssdfsdfdw3vds4dz", tradeName: "AZALIDE 200MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfbdfsssdfsdvbfdw3vds4dz", tradeName: "AZATRIBACT 200MG/5ML SUSP. 22.5 ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvsdvbfddfgdw3vds4dz", tradeName: "AZI-ONCE 200MG/5ML SUSP. 22.5ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvsdvbfdw3vdfds4dz", tradeName: "AZI-ONCE 200MG/5ML SUSP. 30ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdazfdsxfvsdvbfdw3vdfds4dz", tradeName: "AZIWOK 200MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvsdvdsfgdfgbfdw3vdfds4dz", tradeName: "AZOMYCIN 200MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvsdvbdgdffdw3vdfds4dz", tradeName: "AZROLID 200MG/5ML PD. FOR ORAL SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfcvbcvvsdvbdgdffdw3vdfds4dz", tradeName: "AZROLID 200MG/5ML PD. FOR ORAL SUSP. 22.5ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfzczxvsdvbdgdffdw3vdfds4dz", tradeName: "AZROLID 200MG/5ML PD. FOR ORAL SUSP. 30ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvzxczsdvbdgdffdw3vdfds4dz", tradeName: "BADOZITHRO 200MG/5ML PD. FOR ORAL SUSP. 15 ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdas45645gdffdw3vdfds4dz", tradeName: "EPIZITHRO 200MG/5ML 15ML SUSP.", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aas84dz", tradeName: "EPIZITHRO 200MG/5ML 30ML SUSP.", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdas1dfds4dz", tradeName: "GIGAZOCIN 200MG/5ML PD. ORAL SUSP. 25 ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvz1w3vdfds4dz", tradeName: "RAME-ZITHRO 200MG/5ML SUSP. 15 ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvz1ghjghw3vdfds4dz", tradeName: "UNIZITHRIN 100MG/5ML SUSP. 30ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfssdfsdvz1w3vdfds4dz", tradeName: "UNIZITHROCURE 200MG/5ML PD. FOR ORAL SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdasxfvxcvxcz1w3vdfds4dz", tradeName: "XEREXOMAIR 100MG/5ML PD. FOR ORAL SUSP. 30ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadadasnm,nxfvz1w3vdfds4dz", tradeName: "XITHRONE 200 MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadadasxxvxfvz1w3vdfds4dz", tradeName: "XITHRONE 200 MG/5ML SUSP. 25ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadadascvbcvxfvz1w3vdfds4dz", tradeName: "ZISROCIN 100MG/5ML SUSP. 30ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadadasxfvcvbcvbz1w3vdfds4dz", tradeName: "ZITHRODOSE 100MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadazxczxdasxfvz1w3vdfds4dz", tradeName: "ZITHRODOSE 100MG/5ML SUSP. 30ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadaczxcdasxfvz1w3vdfds4dz", tradeName: "ZITHRODOSE 100MG/5ML SUSP. 45ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasgfhfghfgdz", tradeName: "ZITHRODOSE 100MG/5ML SUSP. 60ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasdsadaczxcdasxfvz1w3vdghfds4dz", tradeName: "ZITHROKAN 100MG/5ML PD. FOR ORAL SUSP. 15 ML", genericName: "AZITHROMYCIN 100MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 100, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddfgvdfds4dz", tradeName: "ZITHROKAN 200MG/5ML PD. FOR ORAL SUSP. 15 ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddfgdfgdfvdfds4dz", tradeName: "ZITHROMAX 200MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddfgasdasdvdfds4dz", tradeName: "ZITHROMAX 200MG/5ML SUSP. 22.5ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddzxczxcfgvdfds4dz", tradeName: "ZITHROMAX 200MG/5ML SUSP. 30ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddfzczxczxs4dz", tradeName: "ZITHROPHATE 200MG/5ML SUSP. 15ML", genericName: "AZITHROMYCIN 200MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides", "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin"]), conc: 5 / 200, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin", prec: T.JSArrayOfStringL().of(["Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur", "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs", "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated", "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported", "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases", "Local IV site reactions have been reported with IV azithromycin", "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria", "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin", "Elderly patients may be more susceptible to drug-associated effects on the QT interval", "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported", "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported", "If an allergic reaction occurs, discontinue drug and institute appropriate therapy", "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued"])}), new dosage_provider.Drug.new({id: "aasddfzczxczxczxzczxs4dz", tradeName: "AVEROFECTAN 250MG/5ML SUSP. 60 ML", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczxc9797zczxs4dz", tradeName: "BACTICEFDIN 125 MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczzxczxzczxs4dz", tradeName: "CEDENIR 125MG/5ML DRY SUSP.", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczxc489zxczxzczxs4dz", tradeName: "CEFATHIRD 125MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczxczx456czxzczxs4dz", tradeName: "CEFDIN 125MG/5ML SUSP. 60ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdaaaaa56czxzczxs4dz", tradeName: "DENROCEF 125MG/5ML SUSP. 60ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczxczx4kl;lk;56czxzczxs4dz", tradeName: "DINAR 125MG/5ML SUSP. 100ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasddfzczhkhjjlhxczx456czxzczxs4dz", tradeName: "DINAR 125MG/5ML SUSP. 60ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkljzczxs4dz", tradeName: "EGYNIR 125MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkljzczgfdgfdxs4dz", tradeName: "MAXDINIR 125MG/5ML 60ML SUSP", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkljcbvcbczczxs4dz", tradeName: "MAXDINIR 250MG/5ML 60ML SUSP", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkljzwrwerczxs4dz", tradeName: "MERBACTADIN 125MG/5ML DRY SUSP. 60 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkasdasljzczxs4dz", tradeName: "MERBACTADIN 250MG/5ML DRY SUSP. 60 ML", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkljzczdgdxs4dz", tradeName: "OMNICEF 125MG/5ML SUSP. 40ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzazcljzczxs4dz", tradeName: "OMNICEF 125MG/5ML SUSP. 80 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzazcljzvnvbczxs4dz", tradeName: "RAME-DINIR 125MG/5ML SUSP. 60 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzazcljxcvcxzczxs4dz", tradeName: "RAME-DINIR 250MG/5ML SUSP. 60 ML", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzazclngfhfgjzczxs4dz", tradeName: "SPECTRACEFOCURE 250 MG/5 ML PD. FOR ORAL SUSP. 60ML", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzagjhgzcljzczxs4dz", tradeName: "TORBENER 125MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "CEFDINIR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "aasdjljkzadsfsfzcljzczxs4dz", tradeName: "TORBENER 250MG/5ML PD. FOR ORAL SUSP. 60 ML", genericName: "CEFDINIR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ", prec: T.JSArrayOfStringL().of(["Note differences between twice-daily and once-daily dosing regimens", "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy", "Dosage adjustments may be necessary if CrCl is <30 mL/min", "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy", "Use caution in patients with history of colitis", "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid", "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement"])}), new dosage_provider.Drug.new({id: "cefaclor2", tradeName: "BACTICLOR 250MG/5ML SUSP. 60ML", genericName: "CEFACLOR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor1", tradeName: "BACTICLOR 125MG/5ML SUSP. 60ML", genericName: "CEFACLOR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor3", tradeName: "CECLOR 125MG/5ML SUSP. 75ML", genericName: "CEFACLOR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor4", tradeName: "CECLOR 250MG/5ML SUSP. 75ML", genericName: "CEFACLOR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor5", tradeName: "CEFBIOLOR 250MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "CEFACLOR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor6", tradeName: "CLOROCEF 250MG/5ML SUSP. 60 ML", genericName: "CEFACLOR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor7", tradeName: "MISACLOR 250MG/5ML PD. FOR ORAL 60ML SUSP.", genericName: "CEFACLOR 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefaclor8", tradeName: "MISACLOR 125MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "CEFACLOR 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria", "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy", "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy", "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile"])}), new dosage_provider.Drug.new({id: "cefadroxil1", tradeName: "BIODROXIL 250MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil2", tradeName: "BIODROXIL 500MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 500MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 500, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil3", tradeName: "CEFADROXIL 250MG/5ML PD. FOR ORAL SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil4", tradeName: "CEPHADROL 250 MG/5 ML SUSP. 60 ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil5", tradeName: "CURISAFE 125MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil6", tradeName: "CURISAFE 250MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil7", tradeName: "CURISAFE 500MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 500MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 500, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil8", tradeName: "DURICEF 250 MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil9", tradeName: "DURICEF 500MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 500MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 500, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil10", tradeName: "IBIDROXIL 125MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil11", tradeName: "IBIDROXIL 250 MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil12", tradeName: "IBIDROXIL 500 MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 500MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 500, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil13", tradeName: "LONGICEF 125MG/5ML SUSP. 60 ML", genericName: "CEFADROXIL 125MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 125, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil14", tradeName: "LONGICEF 250MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil15", tradeName: "MEGADROXIL 250MG/5ML ORAL SUSP. 60 ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil16", tradeName: "ROXIL 250MG/5ML SUSP. 100ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection"])}), new dosage_provider.Drug.new({id: "cefadroxil17", tradeName: "ROXIL 250MG/5ML SUSP. 60ML", genericName: "CEFADROXIL 250MG/5ML SUSP", cat: "Antibiotics", contra: T.JSArrayOfStringL().of(["Documented hypersensitivity"]), conc: 5 / 250, minD: 0.0, maxD: 0.0, freq: "PO q12h for 10-14 days", doseNote: "", prec: T.JSArrayOfStringL().of(["Adjust dose in severe renal insufficiency-> (high doses may cause CNS toxicity); prolonged use may result in superinfection"])})]);
    dosage_provider.AntipyreticProvider.__proto__.new.call(this);
    ;
  }).prototype = dosage_provider.AntipyreticProvider.prototype;
  dart.addTypeTests(dosage_provider.AntipyreticProvider);
  dart.addTypeCaches(dosage_provider.AntipyreticProvider);
  dart.setGetterSignature(dosage_provider.AntipyreticProvider, () => ({
    __proto__: dart.getGetters(dosage_provider.AntipyreticProvider.__proto__),
    drugs: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))),
    antipyretics: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))),
    antibiotics: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))),
    commomCold: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))),
    git: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))),
    respiratory: dart.legacy(core.List$(dart.legacy(dosage_provider.Drug)))
  }));
  dart.setLibraryUri(dosage_provider.AntipyreticProvider, I[0]);
  dart.setFieldSignature(dosage_provider.AntipyreticProvider, () => ({
    __proto__: dart.getFields(dosage_provider.AntipyreticProvider.__proto__),
    [_drugs]: dart.fieldType(dart.legacy(core.List$(dart.legacy(dosage_provider.Drug))))
  }));
  dart.trackLibraries("packages/pediatric_dosage/providers/dosage_provider.dart", {
    "package:pediatric_dosage/providers/dosage_provider.dart": dosage_provider
  }, {
  }, '{"version":3,"sourceRoot":"","sources":["dosage_provider.dart"],"names":[],"mappings":";;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;IAGe;;;;;;IACA;;;;;;IAEI;;;;;;;2CAEV,IACA,MACA;IAFA;IACA;IACA;;EACN;;;;;;;;;;;;;;;;;;AAaC,YAAO;wCAAI;;;IACb;;;IAVe,oBAAc,2BAC3B,iCAAS,KAAK,eAAe,oCAAW,6BACxC,iCAAS,KAAK,eAAe,oCAAW,kCACxC,iCAAS,KAAK,eAAe,oCAAW,mCACxC,iCAAS,KAAK,OAAO,oCAAW,2BAChC,iCAAS,KAAK,eAAe,oCAAW;;;EAM5C;;;;;;;;;;;;;;;;;;;;;;;;IAGe;;;;;;IACA;;;;;;IACA;;;;;;IACA;;;;;;IACA;;;;;;IACM;;;;;;IACA;;;;;;IACN;;;;;;IACA;;;;;;IACA;;;;;;IACA;;;;;;;;QAEH;QACD;QACA;QACA;QACA;QACA;QACA;QACA;QACA;QACA;QACA;IAVC;IACD;IACA;IACA;IACA;IACA;IACA;IACA;IACA;IACA;IACA;;EAAM;;;;;;;;;;;;;;;;;;;;;;;;;;AAutJb,YAAO;oCAAI;;;IACb;;AAGE,YAAO,AAAO,AAAiD,sBAA3C,QAAC,WAAY,AAAQ,AAAI,OAAL,SAAQ;IAClD;;AAGE,YAAO,AAAO,AAAiD,sBAA3C,QAAC,WAAY,AAAQ,AAAI,OAAL,SAAQ;IAClD;;AAGE,YAAO,AAAO,AAAiD,sBAA3C,QAAC,WAAY,AAAQ,AAAI,OAAL,SAAQ;IAClD;;AAGE,YAAO,AAAO,AAAyC,sBAAnC,QAAC,WAAY,AAAQ,AAAI,OAAL,SAAQ;IAClD;;AAGE,YAAO,AAAO,AAAiD,sBAA3C,QAAC,WAAY,AAAQ,AAAI,OAAL,SAAQ;IAClD;;;IAxuJW,eAAS,uBAClB,kCACQ,gBACO,0CACE,oBACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,qCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,wCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,uCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,8BACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,2CACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,yCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,8BACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,6BACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,8BACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,yCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,wCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,uCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,yCACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,gDACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,gDACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,+CACN,4BACQ,kCACP,yBACJ,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,2BACA,2LACA,mEAEI,WACA,YACA,AAAE,IAAE,WACJ,kEACI,wDACF,yBACN,kEACA,oFAEN,kCACQ,gBACO,6CACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,yDACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,6CACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,yDACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,8CACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,+CACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,6CACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,gBACO,sDACE,8BACR,uBACG,yBAAC,oBAAoB,uCACvB,AAAE,IAAE,WACJ,YACA,YACA,2BACI,UACJ,yBACJ,6IACA,0GACA,4EACA,mIACA,uKACA,sDACA,sDACA,sQACA,mFAEN,kCACQ,iBACO,2CACE,oCACR,uBACG,yBACN,8JACA,oIAEI,AAAE,IAAE,SACJ,WACA,WACA,uCACI,uDACJ,yBACJ,qLACA,iFACA,+HACA,yWACA,yLACA,2GACA,oGACA,wLACA,wLACA,mJACA,+IACA,4DACA,sgBACA,6GACA,+EACA,2LACA,+DAEN,kCACQ,iBACO,qDAEP,oEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,oCACE,qCACR,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,4EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,sCAEN,kCACQ,iBACO,iDAEP,qFACC,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,4EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,kCACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,iDAEP,qFACC,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,kCACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,uCAEP,qFACC,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,kCACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,sCAEP,qFACC,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,kCACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,sCAEP,oEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,wCAEP,oEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,mCAEP,oEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,kCAEP,wEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,0CAEP,wEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,sCAEP,wEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,uCAEP,wEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,sCAEP,wEACC,uBACG,yBACN,oBACA,mCACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,8SAEN,kCACQ,iBACO,sCAEP,yEACC,uBACG,yBACN,oBACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,gCACA,8BACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,sCAEP,yEACC,uBACG,yBACN,oBACA,2CACA,qCAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,gCACA,8BACA,wDACA,2HACA,6GAEN,kCACQ,iBACO,yCACE,kCACR,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,0SACA,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,uDAEN,kCACQ,iBACO,8CACE,mDACR,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,0SACA,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,0LACA,yDACA,mGACA,uFACA,sCAEN,kCACQ,iBACO,8CACE,mDACR,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,6EACE,yBACJ,wLACA,gIACA,oCACA,mKACA,0SACA,4UACA,+WACA,mFACA,uIACA,4FACA,mJACA,0GACA,yHACA,+MACA,qHACA,gMACA,4NACA,sMACA,mDACA,0LACA,yDACA,mGACA,uFACA,sCAEN,kCACQ,iBACO,uCACE,qCACR,uBACG,yBACN,oBACA,mCACA,mDAEI,WACA,WACA,WACA,uCAEF,4EACE,yBACJ,0LACA,yDACA,mGACA,uFACA,sCAEN,kCACQ,iBACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,iBACO,4CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,iBACO,2CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,iBACO,2CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,iBACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,iBACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,YACA,YACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,oBACO,6CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,sBACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,wBACO,iDACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,2BACO,kDACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,8BACO,qDACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,+BACO,oDACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,mCACO,4CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,oCACO,2CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,qCACO,2CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,sCACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,uCACO,8CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,wCACO,6CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,yCACO,6CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,0CACO,4DACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,2CACO,6CACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,4CACO,4DACE,8BACR,uBACG,yBACN,gFAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,kHACA,mbACA,wHACA,uJACA,sJACA,oEACA,uEACA,2FACA,qEAEN,kCACQ,6CACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,mCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,mCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,kDACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,+CACO,8DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,2CACO,+DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,kDACO,4DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,6DACE,6CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,qDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,oDACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,gDACO,6DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,uDACO,2DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,oDACO,6DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,2DACO,sDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,kDACO,wDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,sDACO,oDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,gCACO,sDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,oCACO,yDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,uCACO,2DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,2CACO,0DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,8CACO,wDACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,+CACO,iDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,qDACO,4DACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,kDACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,+DACO,gDACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,gDACO,+CACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,iDACO,iEACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,kDACO,kDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,gDACO,4CACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,mDACO,+CACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,oDACO,+CACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,mDACO,+CACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,6BACO,+CACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,uDACO,gDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,sDACO,gDACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,qBACO,4CACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,yDACO,4CACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,sCACO,0DACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,iCACO,0DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,uCACO,0DACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,sCACO,qDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,2CACO,mDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,0CACO,yDACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,0BACO,yCACE,8CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,oCACO,6CACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,wCACO,8CACE,4CACR,uBACG,yBACN,0BACA,wGACA,iGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,0CACA,yGACA,8EACA,+DACA,qFACA,sWACA,8HACA,0JACA,wLAEN,kCACQ,2CACO,6CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,6CACO,mDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,0CACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,wCACO,8CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,2CACO,4CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,+CACO,8CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,4CACO,0DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,iDACO,4DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,gDACO,0DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,gDACO,8DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,yCACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,sBACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,6BACO,yDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,oCACO,kDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,yCACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,0CACO,gEACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,yCACO,6DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,6CACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,4CACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,8CACO,8CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,+CACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,8CACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,6CACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,4BACO,gDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,+CACO,6DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,8BACO,6DACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,mCACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,oCACO,iDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,oCACO,+CACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,gCACO,iDACE,oCACR,uBACG,yBACN,+EACA,yGAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8NACE,yBACJ,wOACA,0JACA,4ZACA,0GACA,oZACA,mEACA,oNACA,2LACA,0FACA,sOACA,kGACA,sFACA,oGAEN,kCACQ,uCACO,kDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,cAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,sCACO,gEACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,qCACO,4CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,0CACO,6DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,0CACO,4CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,qCACO,8CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,gDACO,4CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,iDACO,2CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,iCACO,yDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,uCACO,6CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,uCACO,6CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,sCACO,sDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,sCACO,sDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,oCACO,6CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,qCACO,8CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,yCACO,iDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,0CACO,iDACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,2CACO,oEACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,yCACO,4DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,0CACO,4DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCAEF,8iBACE,yBACJ,uEACA,iIACA,6DACA,2GACA,mDACA,sKACA,+LAEN,kCACQ,wBACO,+CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,+CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,4CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,4CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,4DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,+CACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,2DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,wBACO,2DACE,gCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,yNACA,iRACA,wOACA,8PAEN,kCACQ,0BACO,+CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,+CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,6DACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,kDACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,8CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,8CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,8CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,8CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,0BACO,6CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,+CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,gDACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,gDACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,+CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,8CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,sDACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,4CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ,iIAEN,kCACQ,2BACO,2CACE,kCACR,uBACG,yBACN,uCAEI,AAAE,IAAE,WACJ,WACA,WACA,oCACI,UACJ,yBACJ;;;EA2BV","file":"../../../../../packages/pediatric_dosage/providers/dosage_provider.dart.lib.js"}');
  // Exports:
  return {
    providers__dosage_provider: dosage_provider
  };
}));

//# sourceMappingURL=dosage_provider.dart.lib.js.map
